数据链接：
官方服务：
资源简介：
Capecitabine with or without bevacizumab as maintenance therapy in metastatic colorectal cancer: A real-world retrospective study in Vietnamese patients
应用场景：
创建时间：
2025-07-06
相关数据集
Capecitabine with cyclophophamide as maintenance therapy in advanced colorectal cancer patients
Primary outcome(s): In phase I the OBD of capecitabine would be identified using response assessment criteria RECIST version 1.1 and flow cytometry measurement of CEC. So, a twin primary endpoints of
NIAID Data Ecosystem60
Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity Caused By Oxaliplatin in Patients Receiving Combination Chemotherapy for Stage II, Stage III, or Stage IV Colorectal Cancer That Has Been Completely Removed By Surgery
RATIONALE: Calcium gluconate and magnesium sulfate may prevent or lessen neurotoxicity caused by oxaliplatin. It is not yet known whether calcium gluconate and magnesium sulfate are more effective tha
NIAID Data Ecosystem40
Study investigating efficacy of a medicine lanreotide on decrease of chemotherapy induced diarrhoea (CID) in patiens with cancer of colon and rectum.
Primary objectives: Definition of efficacy of lanreotid in the therapy of CID which is defined as a rate of regression of CID to grade G1 from the entry value (grade G3 or G4) according to CTCAE v.4.0
NIAID Data Ecosystem20
Maintenance Bevacizumab Only or Bevacizumab Plus Metronomic Chemotherapy in Advanced Colorectal Cancer
This study consist of 4-months induction first-line chemotherapy with the G.O.N.O. FOLFOXIRI regimen plus bevacizumab followed by maintenance with bevacizumab or bevacizumab plus metronomic chemothera
NIAID Data Ecosystem50
A Randomized Phase III Study Comparing Maintenance Treatment With Fluoropyrimidine + Bevacizumab Versus Fluoropyrimidine After Induction Chemotherapy for a Metastatic Colorectal Cancer
The aim of BEVAMAINT is to improve benefic effect of maintenance therapy after a first line of induction chemotherapy for patients with colorectal cancer
NIAID Data Ecosystem30
